Point Of Care Diagnostics Market Scope And Analysis

  • Report Code : TIPRE00006394
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 245
Buy Now

Point of Care Diagnostics Market Scope and Analysis Report by 2028

Buy Now

Point of Care Diagnostics Market Report Point of Care Diagnostics Market Size and Share Point of Care Diagnostics Market Scope and Analysis

Point of Care Diagnostics Market Report Scope

Report Attribute Details
Market size in 2021 US$ 36 Billion
Market Size by 2028 US$ 82.96 Billion
Global CAGR (2021 - 2028) 12.7%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product
  • Glucose Monitoring Products
  • Infectious Disease Testing Products
  • Cardiometabolic Testing Products
  • Pregnancy and Fertility Testing Products
  • Coagulation Testing Products
  • Tumor/Cancer Marker Testing Products
  • Cholesterol Testing Products
  • Urinalysis Testing Products
  • Hematology Testing Products
  • Other POC Products
By Prescription Mode
  • Prescription-Based Testing and OTC Testing
By End User
  • Professional Diagnostic Centers
  • Home Care
  • Research Laboratories
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • F Hoffmann La Roche Ltd
  • Abbott
  • bioM rieux SA
  • Johnson Johnson Services Inc
  • Nova Biomedical
  • Siemens AG
  • Bio Rad Laboratories Inc
  • BD
  • Danaher Corporation

    • Industry Developments and Future Opportunities:

    Various initiatives taken by key players operating in the global point of care diagnostics market are listed below:

    1. In April 2019, Roche launched VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients.
    2. In April 2019, Bio-Rad Laboratories, Inc. received U.S. Food and Drug Administration (FDA) approval for its BioPlex 2200 Lyme Total Assay. This was an innovative multiplex test method for the diagnosis of Lyme disease.

    Competitive Landscape and Key Companies:

    Companies such as Roche, Bio-Rad, bioMérieux, Siemens Healthineers, Nova Biomedical, Danaher, PTS Diagnostics, and Abbott has been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launch, product up-gradation, patents, expansion of their product portfolio and area expansion for the growth of their organizations. In addition, the companies have invested their efforts to develop products and have received approvals from regulatory bodies such as the US FDA for their products.